Please ensure Javascript is enabled for purposes of website accessibility

AbbVie Is a Dividend Growth Stock at a Bargain Price

By Greg Jones - Updated Feb 12, 2020 at 9:40AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

AbbVie reported fourth-quarter results that topped expectations. Its valuation discount is no longer warranted.

AbbVie (ABBV -0.47%) reported fourth-quarter earnings on Friday that were above consensus and the company raised its guidance for 2020. The results suggested that there was life after Humira, its mainstay immunology product, which is the world's best-selling drug.

On a day when the market was down 1%, AbbVie's shares rose 5%. With the stock still trading at a discount to the market multiple and a dividend yield of 4.6%, AbbVie still has plenty of appeal for the long-term investor. 

Picture of medical technician with a globe

Image source: Getty Images.

AbbVie beat expectations and raised its guidance

AbbVie's results were resoundingly positive. Worldwide revenues rose 5.3% operationally to $8.7 billion despite international Humira sales declining 25% -- excluding this, revenues were up 11%. Adjusted earnings per share (EPS) grew 16% year over year and came in a penny ahead of consensus. And next year's guidance was raised to a range of $9.61 to $9.71 per share, with the midpoint representing an increase of 8.1%.

It's no small wonder, then, that the stock rose as much as it did. For much of last year, AbbVie's shares lagged the overall market. Much of this had to do with concern about Humira, which accounted for up to 60% of AbbVie's sales and a higher percentage of its profits, and which was scheduled to go off-patent in 2023 in the U.S. The company's fourth-quarter results went a long way in mitigating these fears.

Concerns about Humira are exaggerated

Although Humira still accounted for a hefty 56% of sales in the fourth quarter, stronger growth was seen in the company's other drugs. Sales of AbbVie's hematological oncology drugs grew 39% to over $1.5 billion, driven by Imbruvica and Venclexta which combined for $5.5 billion in sales in 2019. In the immunology area, Skyrizi and Rinvoq exceeded expectations and sales are expected to more than triple next year to $1.7 billion. This highlights the company's R&D efforts which, as CEO Richard A. Gonzalez points out, over the last seven years has led to the development of drugs generating $9 billion in sales in 2019.  

To further wean its dependency off Humira, AbbVie will soon complete its acquisition of Allergan. Allergan brings with it $16 billion in annual revenue in mostly unrelated therapeutic markets, and is expected to be immediately accretive, contributing 10% to adjusted EPS in the first year. The combined AbbVie/Allergan entity will rank fourth in overall revenues and third in operating cash flow, creating significant scale in an industry where the costs of delivering a new drug to the market is in excess of $2 billion and rising.  

This cash flow should suffice in funding further dividend increases. Having grown its dividend 195% since separating from Abbott Laboratories in 2013, AbbVie still has plenty of room to grow it further. And at current yield of 4.6%, the company's dividend is among the highest in the healthcare sector. With the stock trading at half the market price-to-earnings ratio, AbbVie represents a rare bargain in the healthcare sector that is too good to miss.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$151.01 (-0.47%) $0.71
Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$113.24 (0.71%) $0.80
Allergan plc Stock Quote
Allergan plc
AGN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.